MedImmune And National Institutes Of Health Begin Clinical Testing Of A Live, Attenuated Intranasal Vaccine Against An H5N1 Avian Influenza Virus
submited by kickingbird at Jun, 16, 2006 16:18 PM from Medical News Today
MedImmune, Inc.(Nasdaq: MEDI) announced today that the National Institutes of Health (NIH)has begun enrolling participants in a Phase 1 study of an intranasal H5N1influenza vaccine candidate based on the company´s live, attenuated vaccinetechnology. [click link for full article]
See Also:
Latest news in those days:
- Primers and probes for H5 and N1 qRT-PCR detection [CNIC] 1 hours ago
- USDA: Actions to Protect Livestock Health From Highly Pathogenic H5N1 Avian Influenza 1 days ago
- USFDA: Updates on Highly Pathogenic Avian Influenza (HPAI) 2 days ago
- Resources: Consensus sequences for U.S. H5N1 clade 2.3.4.4b 3 days ago
- USDA Publishes H5N1 Influenza A Virus Genetic Sequences on publicly available site 3 days ago
[Go Top] [Close Window]